Compare Airbnb, Inc. (ABNB) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Airbnb, Inc. vs Incyte Corporation — how do they compare? Airbnb, Inc. trades at $179.92 (market cap $110.76B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Airbnb, Inc. is far larger — about 4.5× Incyte Corporation's market cap, and Airbnb, Inc. is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| ABNB | INCY | |
|---|---|---|
Market Cap | $110.76B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $129.93 |
52-Week Low | $111.54 | $81.61 |
Enterprise Value | $101.19B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABNB trades at $179.40, down 2.87% over 24 hours, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported Q2 2026 EPS of $1.37, beating expectations, and revenue growth continues with a 20.45% net income margin. Recent news highlights AI-driven growth and expansion into hotels and travel services.
Outlook is positive with strong analyst support and AI integration boosting efficiency, but high valuation ratios and competitive pressures pose risks. The consensus price target is $173.26, slightly below current price, indicating cautious optimism amid growth momentum.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
